Holtorf Anke-Peggy, Bertelsen Neil, Jarke Hannes, Dutarte Maria, Scalabrini Silvia, Strammiello Valentina
Health Outcomes Strategies GmbH, Basel, Switzerland.
College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Int J Technol Assess Health Care. 2024 Dec 19;40(1):e81. doi: 10.1017/S0266462324004707.
There are wide variations in the practices of patient involvement in health technology assessment (HTA) in Europe. The field is lacking a consensus on good practices, leading to divergent processes, methods, and evaluation of patient involvement. To identify potential good practice approaches and current gaps, a structured online survey was conducted among HTA stakeholders, including HTA practitioners, patient stakeholders, industry representatives, and others who had experienced patient involvement in HTA.
The questionnaire was co-created by HTA experts, patient stakeholders, and industry representatives and disseminated between 29 April and 14 September 2022.
Responses (n = 168) were submitted from thirty-two European countries by HTA practitioners (n = 33), patient stakeholders (n = 75), industry stakeholders (n = 42), providers (n = 5), academics (n = 7), and others (n = 6). The responses indicated that "is the principle rationale for conducting HTA. In terms of the importance of patient involvement, there was consensus across stakeholder groups that "" and that patient involvement is important "". Shortcomings were identified in the lack of systematic and transparent processes, an unsatisfactory level of information and guidance, and minimal communication and collaboration.
The diverse stakeholders who responded highlighted the need for improving specific aspects of patient involvement practices, including better guidance and information, a more consistent flow of communication between the HTA body and participating patient stakeholders, and the need to develop and implement a consensus on good practices.
在欧洲,患者参与卫生技术评估(HTA)的实践存在很大差异。该领域在良好实践方面缺乏共识,导致患者参与的流程、方法和评估各不相同。为了确定潜在的良好实践方法和当前存在的差距,我们对HTA利益相关者进行了一项结构化在线调查,这些利益相关者包括HTA从业者、患者利益相关者、行业代表以及其他有患者参与HTA经验的人。
该问卷由HTA专家、患者利益相关者和行业代表共同创建,并于2022年4月29日至9月14日期间进行了分发。
来自32个欧洲国家的HTA从业者(n = 33)、患者利益相关者(n = 75)、行业利益相关者(n = 42)、提供者(n = 5)、学者(n = 7)和其他人员(n = 6)提交了回复(n = 168)。回复表明“是进行HTA的主要理由。在患者参与的重要性方面,各利益相关者群体达成了共识,即‘’且患者参与很重要”。调查发现了一些不足之处,包括缺乏系统和透明的流程、信息和指导水平不尽人意,以及沟通与协作极少。
做出回复的不同利益相关者强调了改进患者参与实践特定方面的必要性,包括提供更好的指导和信息、HTA机构与参与的患者利益相关者之间更一致的沟通流程,以及制定和实施关于良好实践的共识的必要性。